SCHEMBL1898462

SCHEMBL1898462

Nc1nc(Cl)nc2c(-c3cnc4ccccc4c3)csc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.43
PDGFRA P16234 3/20 0.43
HTR2C P28335 1/20 0.39
PIM1 P11309 3/20 0.39
BMPR1B O00238 1/20 0.39
PIK3C2G O75747 1/20 0.39
CDKL5 O76039 1/20 0.39
TYK2 P29597 1/20 0.39
CLK2 P49760 1/20 0.39
DYRK1A Q13627 1/20 0.39
STK32B Q9NY57 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
IRAK3 Q9Y616 1/20 0.39
PIM3 Q86V86 2/20 0.38
PIM2 Q9P1W9 2/20 0.38
CYP2A6 P11509 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1682843 0.79 PTK2 (0.50) PDGFRBPDGFRAPIM1BMPR1BPIK3C2G
SCHEMBL1899772 0.76 HTR2C (0.43) HTR2CDYRK1APIK3CDPIK3CAEPHB4
SCHEMBL12676074 0.72 PTK2 (0.57) PIM1PTK2PIK3CAABL1KDR
SCHEMBL1899044 0.70 MAP4K4 (0.45) HTR2CPTK2
SCHEMBL20665641 0.70 PDGFRB (0.42) PDGFRBPDGFRAPIM1CLK2DYRK1A
SCHEMBL26883415 0.69 PDGFRB (0.41) PDGFRBPDGFRAPIM1CLK2DYRK1A
SCHEMBL8499476 0.68 PDGFRB (0.54) PDGFRBPDGFRAPIM1PIM3PIM2
SCHEMBL2624503 0.68 PDGFRB (0.54) PDGFRBPDGFRAPIM1BMPR1BPIK3C2G
SCHEMBL7233491 0.67 RAB9A (0.61) PDGFRBPDGFRAPIM1CYP2A6CA12
SCHEMBL1901218 0.67 PTK2 (0.61) TYK2PTK2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422307-B2 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2016-08-23 US disclosed
US-9422307-B2 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2016-08-23 US disclosed
US-9422307-B2 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2016-08-23 US disclosed
US-20130012703-A1 2,4,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-01-10 US disclosed
US-20130012703-A1 2,4,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-01-10 US disclosed
US-20130012703-A1 2,4,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-01-10 US disclosed
WO-2011062372-A2 2, 4, 7 -SUBSTITUTED THIENO [3, 2 -D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-05-26 WO disclosed
WO-2011062372-A2 2, 4, 7 -SUBSTITUTED THIENO [3, 2 -D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012703-A1 2,4,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS CDK2, TK1, MAP4K2 PDGFRB 297/4885PDGFRA 281/4885HTR2C 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.